Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
